Truemeds reportedly in advanced talks to acquire DealShare at $90M valuation

The proposed share-swap deal would value DealShare about 95% below its 2022 peak and could give online pharmacy Truemeds access to the value-commerce firm’s cash reserves and smaller-city sourcing network. Final terms remain under negotiation.

— Source publishedMon, 31 Aug, 2026, 13:08 IST·First seen Mon, 31 Aug, 2026, 13:14 IST·Source Inc42 · Buzz

What happened

Online pharmacy Truemeds is reportedly in advanced share-swap talks to acquire DealShare for just over $90 million, largely for its cash reserves and

Key facts

  • DealShare proposed valuation: over $90 million
  • DealShare peak valuation: $1.7 billion in 2022
  • Truemeds expected share-issue valuation: about $600 million
  • DealShare cash balance: over $90 million
  • DealShare total funding: nearly $400 million
  • DealShare Series E: $165 million
  • Subsequent DealShare infusion: $45 million
  • DealShare FY25 revenue: about ₹432 crore
  • DealShare FY24 revenue: ₹499 crore
  • DealShare FY23 revenue: nearly ₹1,963 crore
  • DealShare FY25 loss: ₹87.65 crore
  • DealShare FY24 loss: ₹167 crore
  • Truemeds total funding: over $175 million
  • Truemeds Series C: $85 million
  • Truemeds valuation after Series C: over $400 million

Why this matters

This reported transaction would give Truemeds a faster route into value commerce and non-metro infrastructure, using DealShare’s cash reserves and supply network rather than building them organically.

What to watch

  • Confirmation of exclusivity, signed definitive agreements, shareholder approvals or regulatory filings.
  • Disclosed deal structure, especially cash-on-balance-sheet treatment, share-swap ratio, earn-outs and DealShare debt or liability assumptions.
  • Whether DealShare continues operating as a separate brand, retains founders and preserves its delivery footprint.
  • Evidence of Truemeds adding grocery, FMCG, wellness or household categories beyond prescription and generic medicines.
  • Changes in DealShare vendor terms, workforce levels, warehouse operations or serviceable-city coverage before closing.
  • Funding announcements from Truemeds or existing DealShare investors that indicate integration financing or a rescue-capital requirement.
  • Conduct diligence on DealShare's unrestricted cash, vendor payables, logistics commitments, customer liabilities and investor liquidation preferences.
  • Negotiate a structure with performance-linked share consideration, escrow and protections around cash use and undisclosed obligations.
  • Map overlap between Truemeds' pharmacy delivery lanes and DealShare's tier-2/3 sourcing and fulfilment hubs before committing to full-network retention.
  • Pilot cross-selling of OTC, wellness, chronic-care essentials and value household baskets in selected smaller-city markets.
  • Rationalize duplicate technology, procurement, dark-store or warehouse capacity and loss-making service areas after close.
  • Use the transaction narrative to pursue follow-on capital from investors seeking a consolidated, profitable health-commerce platform.

Also reported by